ArticleEuropean heart journal. Digital health2025
Interpretable predictive value of including HDL-2b and HDL-3 in an explainable boosting machine model for multiclass classification of coronary artery stenosis severity in acute myocardial infarction patients.
Article in European heart journal. Digital health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aims: The aim of this study was to use explainable boosting machine (EBM) to evaluate the predictive value of HDL-2b and HDL-3 levels in comparison with traditional lipid parameters in three-class classification of coronary artery stenosis severity in acute myocardial infarction (AMI) patients. Methods and results: In this cross-sectional study, 1200 AMI patients were evaluated. HDL subtypes were quantified via microfluidic chip detection, and stenosis severity was assessed via the Gensini scoring system. The Gensini scores were divided into three groups: low group (<36.5), moderate group (36.5-72), and high group (>72). Explainable boosting machine, an interpretable machine learning technique, was employed to assess the predictive value of HDL-2b and HDL-3 compared with traditional lipid markers. Explainable boosting machine was used as the main model in this study, whereas logistic regression, XGBoost, and Random Forest were selected as reference models for predictive performance. Model performance was evaluated using receiver operating characteristic curves. The HDL-3 (%) values were divided into three risk categories: low (>43), moderate (30-43), and high (<30). The incorporation of HDL-2b and HDL-3 levels into lipid profiling significantly increased the group importance scores. The macro-average area under the curve values for the four models were as follows: 0.56 for the logistic model, 0.54 for the EBM model, 0.50 for the Random Forest model, and 0.49 for the XGBoost model. Conclusion: HDL-3 provides superior predictive value for evaluating coronary artery stenosis severity in AMI patients compared to HDL-2b and other conventional lipid markers.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.